ArticleComputational and structural biotechnology journal2025
FAM117A and PIGU regulate the trilogy of gastric carcinogenesis.
Article in Computational and structural biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) develops through a multistep process; however, the molecular mechanisms driving the progression from normal gastric mucosa to precancerous lesions and ultimately to GC remain incompletely understood. Here, this study performed whole-transcriptome sequencing and ATAC-seq on normal gastric mucosa (N), gastric precancerous lesions (P), and gastric tumor tissues (T) to profile chromatin accessibility, lncRNAs, miRNAs, and mRNAs. Differential expression and KEGG pathway analyses identified key hub genes driving gastric carcinogenesis. A core competing endogenous RNA (ceRNA) network revealed critical regulatory lncRNAs for H19 and SNHG3. Through integrative analysis of ATAC-seq and whole-transcriptome sequencing, FAM117A and PIGU were identified as potential key regulatory factors. Experimental validation, including western blot, RT-qPCR, plasmid transfection and immunohistochemistry, confirmed FAM117A and PIGU as pivotal targets. Functional assays demonstrated that FAM117A and PIGU regulate the p53 signaling pathway and modulate cell adhesion molecules (N-cadherin and E-cadherin), highlighting their involvement in abnormal proliferation and tumor metastasis during GC progression. These findings identify FAM117A and PIGU as novel biomarkers and potential therapeutic targets, providing mechanistic insights into gastric carcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.